CAS 250694-07-6

3-[(tetradecylcarbamoyl)amino]-4-(trimethylammonio)butanoate

Description:

3-[(Tetradecylcarbamoyl)amino]-4-(trimethylammonio)butanoate, with the CAS number 250694-07-6, is a synthetic compound characterized by its amphiphilic nature, which arises from its long hydrophobic tetradecyl chain and a positively charged trimethylammonium group. This unique structure allows it to interact with both aqueous and lipid environments, making it useful in various applications, including as a surfactant or in drug delivery systems. The presence of the carbamoyl group contributes to its stability and solubility in biological systems. Additionally, the butanoate moiety may enhance its interaction with biological membranes. The compound's properties, such as its surface activity, solubility, and potential biocompatibility, are influenced by the balance between its hydrophobic and hydrophilic regions. Overall, this substance is of interest in fields such as medicinal chemistry, nanotechnology, and materials science, where its unique characteristics can be leveraged for innovative applications.

Formula: C₂₂H₄₅N₃O₃

InChI: InChI=1/C22H45N3O3/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-23-22(28)24-20(18-21(26)27)19-25(2,3)4/h20H,5-19H2,1-4H3,(H2-,23,24,26,27,28)

SMILES: CCCCCCCCCCCCCCN=C(NC(CC(=O)O)C[N+](C)(C)C)[O-]

Synonyms:

• 4-Trimethylammonio-3-((Tetradecylcarbamoyl)Amino)Butyrate

(R)-3-(3-Tetradecylureido)-4-(trimethylammonio)butanoate

CAS: 250694-07-6

Formula: C₂₂H₄₅N₃O₃

Purity: 98.0%

Molecular weight: 399.6110

Ref: IN-DA002QD4

ST1326

CAS: 250694-07-6

ST1326 is a carnitine-based compound that has been shown to exhibit anti-cancer activity. It was found to reduce the mitochondrial membrane potential in prostate cancer cells, as well as inhibit the growth of these cells. ST1326 also reduces the expression of an amp-activated protein kinase, which can lead to apoptosis, and inhibits transcriptional regulation. ST1326 has also been shown to have a direct effect on cervical cancer by inhibiting the phosphorylation of c-Jun N-terminal kinase (JNK) and reducing its downstream signaling pathways. This drug binds to fatty acids and can be used for the treatment of diabetic patients with congestive heart failure.

Formula: C₂₂H₄₅N₃O₃

Purity: Min. 95%

Molecular weight: 399.61 g/mol

Ref: 3D-AKA69407

Teglicar

CAS: 250694-07-6

Teglicar is a selective and reversible liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor.

Formula: C₂₂H₄₅N₃O₃

Purity: 98%

Color and Shape: Solid

Molecular weight: 399.61

Ref: TM-T13113